With the increase in global and domestic demand for biosimilars along with the shortage in the Egyptian market suffering biosimilars are only imported, the government is constantly facing the challenge of allocating the necessary foreign currencies needed to import biological products with its limited budget.

EIPICO, which established the first biotechnology centre in the region, plans to enter the field of production of biological preparations and alternatives by establishing the first facility dedicated to manufacturing biological preparations and substitutes (EIPICO 3) in the MENA region for the production of pharmaceuticals and pharmaceutical products starting from the cell line all the way through upstream, downstream, formulation and packing to the final dosage form.

EIPICO 3 will manufacture 7 biological products, 4 monoclonal antibodies (MABs) and 3 biopharmaceutical proteins with an investment cost estimated at 1.2 billion Egyptian pounds.